

REGENERON PHARMACEUTICALS INC
Form 8-K
April 02, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 2, 2013 (April 2, 2013)

REGENERON PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

New York
(State or other jurisdiction

of Incorporation)

000-19034
(Commission

File No.)

13-3444607
(IRS Employer

Identification No.)

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707

(Address of principal executive offices, including zip code)

(914) 847-7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Data from a Phase 2a trial of dupilumab (REGN668/SAR231893), an investigational, high affinity, subcutaneously administered, fully human monoclonal antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha) in patients with moderate-to-severe asthma, is scheduled to be presented at the American Thoracic Society (ATS) International Conference held in Philadelphia, Pennsylvania from May 17-22, 2013. The data will be presented during the Late Breaking Abstracts in Clinical Trials Session on May 21, 2013 at 9:00AM EDT. The title and abstract can be found on the ATS conference website.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 2, 2013

REGENERON PHARMACEUTICALS, INC.

By: /s/ Joseph J. LaRosa

Name: Joseph J. LaRosa

Title: Senior Vice President, General Counsel and Secretary